MedTrace Logo

Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)

NCT01306409 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2011-10-19

No results posted yet for this study

Summary

The purpose of this study is to gain information on reticulocyte neocytolysis in patients treated with ESA with regard to different types of ESA.

Conditions

  • Renal Anemia

Interventions

DRUG

cera, darbepoetin, epoetin-beta

Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk

DRUG

ESA

Sequential application of three different ESA

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Michael Dickenmann, MD · Transplantation immunology and nephrology, unversity hospital Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-07-31
Completion
2011-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01306409 on ClinicalTrials.gov